Retatrutide: Dosage & Administration
Part of the Retatrutide Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Clinical Trial Dosing
| Parameter | Detail |
|---|---|
| Route | Subcutaneous injection |
| Frequency | Once weekly |
| Starting dose | Titrated from 1–2 mg |
| Maintenance doses studied | 4 mg, 8 mg, 12 mg weekly |
| Titration | Increase every 4 weeks to target dose |
Dose titration is essential to minimize gastrointestinal side effects. Starting at full dose without titration significantly increases nausea, vomiting, and diarrhea — consistent with all GLP-1 class compounds.
Titration Schedule
Phase 2 trials used gradual dose escalation over several weeks to reach the target maintenance dose. The highest dose group (12 mg) started at a lower dose and increased every 4 weeks. This titration approach reduces GI side effects that are most pronounced during early exposure to GLP-1 receptor activation.
Research Reconstitution
Retatrutide is not yet commercially available. For research applications involving lyophilized peptide, use the peptide calculator for reconstitution volumes. See the reconstitution guide for preparation and the injection guide for technique.